GLP1R and diabetic kidney disease: Long-acting GLP-1 receptor agonists have shown excellent efficacy in reducing cardiovascular risks and safety profiles in T2DM patients at high cardiovascular risk, including those with DKD, in addition to their many positive characteristics.